Carmignac Gestion’s Cidara Therapeutics CDTX Stock Holding History

Carmignac Gestion’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,896	Closed	-$4.17M	–	118
2025 Q4	$4.17M	Buy	+18,896	New	+$3.05M	0.06%	79

Carmignac Gestion's CDTX Position: Q1 2026 in Review

Carmignac Gestion sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 18,896 shares — an estimated $4.17M sold.

Carmignac Gestion first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $4.17M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Carmignac Gestion reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Carmignac Gestion sold 18,896 Cidara Therapeutics shares in Q1 2026, an estimated $4.17M.
Carmignac Gestion first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Carmignac Gestion's Cidara Therapeutics position peaked at $4.17M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Carmignac Gestion's 13F filing for Q1 2026, filed 15 Jun 2026.